This is an exciting opportunity to join Pfizer’s dermatology franchise - an agile, innovative, groundbreaking team. The Dermatology TA has an industry leading pipeline and is poised for continued growth and success. The Dermatology team was responsible for two of our 25 by 2025 launches, LITFULO and CIBINQO. LITFULO is a JAK3/TEC molecule that received approval in June 2023 and is the first and only FDA-approved treatment for severe alopecia areata (AA) in adolescents (ages 12-17) and adults. Currently, there are only two other FDA-approved medicines for AA in adults, so LITFULO delivers on a critical unmet need for people suffering with the severe AA. CIBINQO is an oral JAK inhibitor for moderate to severe Atopic Dermatitis that received FDA breakthrough designation and was approved in the US in mid-January 2022. The CIBINQO marketing team comprises a group of talented, diverse, tenacious colleagues and attracts employees focused on developing or enhancing their growth mindset. With several Pfizer Firsts under their belt, they remain focused on building excellent, innovative strategies with patients at the center of their mission. The team is driven by an unrelenting determination to embody Pfizer’s values and to be the catalyst for every team member’s success. They harness their individual and collective strengths and embrace the courage to pursue boldness. The CIBINQO HCP Director is a critical role that will lead all field force marketing efforts and support the strategy and execution of key HCP-focused initiatives. This high-visibility position will lead several key projects. The selected colleague will report to the US CIBINQO Brand lead and will work closely with cross-functional colleagues and external vendors.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Director
Number of Employees
5,001-10,000 employees